Psychedelics, Cannabis, GLP-1s Face Converging Policy Shifts in 2026

Three Drug Classes Under Simultaneous Policy Review

Psychedelics, cannabis, and GLP-1 receptor agonists are undergoing concurrent policy evaluations this summer. Each substance class operates under different federal schedules and approval pathways, yet all three are subject to active rulemaking or legislative action as of July 2026.

The timing's unusual. Psychedelics remain Schedule I federally despite state-level therapeutic programs in Oregon and Colorado. Cannabis sits in a rescheduling holding pattern following the DEA's April 2024 proposal to move it to Schedule III. GLP-1 drugs like semaglutide face new utilization management rules from CMS and private payers.

Cannabis Rescheduling Remains Stalled in Administrative Review

The DEA's proposed shift of cannabis from Schedule I to Schedule III has been under public comment and administrative law review for over two years. The agency received more than 43,000 public comments following the April 2024 Notice of Proposed Rulemaking but hasn't issued a final rule.

If finalized, the rescheduling would preserve federal prohibition but allow state-legal cannabis businesses to deduct ordinary business expenses under IRC 280E. It wouldn't legalize interstate commerce or resolve banking access issues. For full background on this story, see the CannIntel topic hub on Cannabis Drug Policy Reform.

State Psychedelic Programs Expand Despite Federal Schedule I Status

Oregon and Colorado have launched regulated psilocybin service programs, creating a state-legal framework that exists entirely outside federal approval. Oregon's program began accepting client sessions in June 2023. Colorado's went live in December 2024.

Both states restrict use to licensed service centers with trained facilitators. Neither allows home use or retail sales. The model differs sharply from cannabis's state-legal retail structure, reflecting psilocybin's current lack of FDA approval for any indication.

The state programs function as controlled research environments, not consumer markets—a design choice intended to preempt federal enforcement.

GLP-1 Utilization Management Tightens Amid Demand Surge

Medicare and private insurers have imposed new prior authorization requirements and step-therapy protocols for GLP-1 drugs in 2026. CMS finalized new coverage criteria in May, requiring documented lifestyle intervention before approval for obesity indications.

Prescriptions exploded. The drugs—semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound)—saw U.S. prescriptions exceed 9 million per month in early 2026, straining payer budgets, and the policy changes aim to limit use to patients meeting specific BMI and comorbidity thresholds while controlling costs that threatened to overwhelm formulary planning cycles.

What the Convergence Signals for Drug Policy in 2026

Simultaneous movement on three unrelated drug classes reflects broader pressure on federal scheduling and approval systems. Psychedelics and cannabis challenge the CSA's therapeutic-versus-abuse framework. GLP-1s test the payer system's ability to manage blockbuster drugs with broad off-label demand.

We're watching three indicators: DEA's final cannabis scheduling decision (expected Q3 2026), FDA's review of MDMA and psilocybin New Drug Applications (decision dates in August and November 2026), and CMS's enforcement of GLP-1 coverage restrictions through the fall formulary cycle.